Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 26 Main Street, Suite 101 CHATHAM NJ 07928 |
Tel: | N/A |
Website: | https://www.tonixpharma.com |
IR: | See website |
Key People | ||
Seth Lederman Chairman of the Board, President, Chief Executive Officer | Bradley Saenger Chief Financial Officer, Treasurer | Jessica Edgar Morris Chief Operating Officer |
Zeil Rosenberg Executive Vice President - Medical | Gregory M. Sullivan Secretary, Chief Medical Officer |
Business Overview |
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. |
Financial Overview |
For the fiscal year ended 31 December 2023, Tonix Pharmaceuticals Holding Corp revenues increased from $0K to $7.8M. Net loss applicable to common stockholders increased less than 1% to $116.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Stock-based Compensation in SGA decrease of 19% to $6.4M (expense). |
Employees: | 103 as of Apr 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $7.77M as of Dec 31, 2023 |
EBITDA (TTM): | -$114.09M as of Dec 31, 2023 |
Net annual income (TTM): | -$116.66M as of Dec 31, 2023 |
Free cash flow (TTM): | -$109.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 84,490,862 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |